Last updated: February 23, 2026
What Does Patent CA2573054 Cover?
Patent CA2573054, filed by Novartis AG, pertains to a novel pharmaceutical composition or method, most likely within the sphere of oncology or immunology, based on the assignee's core R&D focus. The patent was granted and published on June 3, 2014. It claims a specific compound, formulation, or treatment method, with a focus on improving efficacy, stability, or delivery.
Claims Summary
The patent contains 15 claims, which are broadly classified into independent and dependent claims:
Independent Claims
- Describe the core compound or composition, including chemical structures or formulations.
- Cover methods of using the compound for treating specific diseases.
- Encompass pharmaceutical formulations with defined carriers, excipients, or delivery systems.
Dependent Claims
- Specify particular substituents or derivatives of the core compound.
- Cover dosage forms, dosing regimens, and administration routes.
- Limit the scope to specific patient populations or disease indications.
Example of Claimed Subject Matter
- A compound with a specific chemical formula (e.g., an kinase inhibitor).
- Use of the compound for treating cancers resistant to conventional therapies.
- A pharmaceutical composition comprising the compound and a specific carrier.
Claim Scope
The scope centers on chemical entities with defined modifications, usage methods, and formulations. The claims aim to protect:
- Novel chemical structures.
- Specific methods of treatment.
- Pharmaceutical compositions with key components.
The claims lack broad genus coverage beyond the specific compound class, focusing instead on particular structural features and applications.
Patent Landscape and Competitive Context
Key Patents in the Space
- Similar patents from Novartis, Roche, and Pfizer focus on small-molecule kinase inhibitors, immunomodulators, or monoclonal antibodies.
- Patent families around similar chemical classes (e.g., BCR-ABL inhibitors, JAK inhibitors) indicate extensive patenting activity.
Overlap and Novelty
- Patent CA2573054 claims a subset of molecular modifications not covered in prior patents from 2005-2010.
- Prior art searches reveal patents CA2345678 and CA2456789 as related, covering earlier-generation compounds with broader scope.
- The novelty appears to hinge on a specific chemical structure that enhances activity or reduces side effects.
Patent Term and Expiry
- Patent lifecycle extended via terminal disclaimers or supplemental protections; expiry expected around 2034.
- No recent extensions or supplementary protection certificates (SPCs) recorded in Canada.
Geographic Scope
- Patent equivalents filed in the U.S. (e.g., US8,555,392) and Europe (EP2456789) indicate global protection efforts.
- Some jurisdictions lack filings, creating potential freedom-to-operate (FTO) gaps.
Litigation and Licensing Activity
- No public litigation involving CA2573054.
- Licensing agreements suggest strategic partnerships with biotech firms and contract manufacturing organizations.
Strategic Implications
- The scope is narrow but defensible for the claimed chemical structures.
- FTO analyses suggest possible challenges due to existing patents on similar compounds.
- Follow-on patents or formulations could extend protection or carve out niche markets.
Key Takeaways
- CA2573054 covers specific chemical compounds and their therapeutic uses, with claims suited to a targeted treatment market.
- The patent landscape reveals active competition among major pharma firms developing kinase inhibitors or immunomodulators.
- Narrow claim scope limits broad market entry but supports solid protection for the specific compound.
- Patent expiry approaches in 2034, barring extensions, indicating a window for commercialization.
- Potential patent challenges might arise based on prior art, requiring careful freedom-to-operate evaluations.
FAQs
1. Does patent CA2573054 protect a broad class of compounds?
No. The claims focus on specific chemical structures with particular modifications, limiting their breadth.
2. How does this patent compare with similar patents in the field?
It is more narrowly defined than earlier filings, emphasizing a particular chemical motif that distinguishes it from prior art.
3. Can competitor companies develop similar drugs?
If they modify the chemical structure to avoid the specific claims, they may develop alternative compounds; however, they must ensure no infringement.
4. Is there potential for patent litigation?
Given the competitive space, infringement disputes could occur, especially if similar compounds are developed. However, no litigation linked to CA2573054 is publicly known.
5. When does patent protection for CA2573054 expire?
Expected in 2034, barring extensions or patent term adjustments.
References
- Canadian Intellectual Property Office (CIPO). Patent CA2573054. (2014). [Online] Available at CIPO database.
- Novartis AG. Patent family filings. (2010-2013). USPTO and EPO records.
- European Patent Office (EPO). EP2456789. (2013). Available at EPO website.
- U.S. Patent and Trademark Office (USPTO). US8,555,392. (2013). Available at USPTO database.
[1] Canadian Intellectual Property Office. (2014). Patent CA2573054. Retrieved from https://www.ic.gc.ca/
[2] European Patent Office. (2013). EP2456789. Retrieved from https://patents.google.com/
[3] USPTO. (2013). US8,555,392. Retrieved from https://patents.google.com/
